Cormorant Asset Management’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Cormorant Asset Management’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-75,920	Closed	-$1.79M	–	86
2016 Q3	$1.79M	Hold	75,920	–	–	0.2%	67
2016 Q2	$1.9M	Buy	75,920 +920	+1%	+$43.8K	0.27%	62
2016 Q1	$3.31M	Hold	75,000	–	–	0.5%	48
2015 Q4	$4.09M	Hold	75,000	–	–	0.49%	49
2015 Q3	$3.14M	Hold	75,000	–	–	0.5%	49
2015 Q2	$3.9M	Buy	+75,000	New	+$4.03M	0.52%	47

Other funds holding CYAD

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cormorant Asset Management's CYAD Position: Q4 2016 in Review

Cormorant Asset Management sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q4 2016, closing a stake of 75,920 shares — an estimated $1.79M sold.

Cormorant Asset Management first reported a position in CYAD in Q2 2015 and held it in 6 quarters. The position peaked at $4.09M in Q4 2015. 6 funds tracked by Wall St. Rank hold CYAD as of Q4 2016.

Cormorant Asset Management reported no remaining Celyad Oncology SA American Depositary Shares position as of Q4 2016 after selling out during the quarter.
Cormorant Asset Management sold 75,920 Celyad Oncology SA American Depositary Shares shares in Q4 2016, an estimated $1.79M.
Cormorant Asset Management first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2015 and held it in 6 quarters.
Cormorant Asset Management's Celyad Oncology SA American Depositary Shares position peaked at $4.09M in Q4 2015.
6 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q4 2016.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.